SCHEMBL5772049

SCHEMBL5772049

COc1ccc(S(=O)(=O)N[C@](Cc2ccccc2)(NC(=O)OC2COC3OCCC23)[C@@H](C)O)cc1CC(C)(C)CCN

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.46
KCNE1 P15382 1/20 0.46
KCNQ1 P51787 1/20 0.46
KCNH2 Q12809 1/20 0.46
SCN5A Q14524 1/20 0.46
KCND3 Q9UK17 1/20 0.46
KMT2A Q03164 1/20 0.31
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
LMNA P02545 2/20 0.30
MLNR O43193 1/20 0.30
ABCB11 O95342 1/20 0.30
CTSD P07339 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP3A5 P20815 1/20 0.30
CNR1 P21554 1/20 0.30
TBXAS1 P24557 1/20 0.30
ADRA1A P35348 1/20 0.30
THRB P10828 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1602534 1.00 ABCB1 (0.46) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL1600751 1.00 ABCB1 (0.46) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL1602713 0.97 ABCB1 (0.45) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL1601307 0.97 ABCB1 (0.45) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL1603130 0.90 ABCB1 (0.42) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL1601811 0.90 ABCB1 (0.42) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL1600573 0.89 ABCB1 (0.41) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL1601847 0.89 ABCB1 (0.41) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL5773477 0.86 ABCB1 (0.43) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL5773719 0.86 ABCB1 (0.43) ABCB1KCNE1KCNQ1KCNH2SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637518-A2 Inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-03-22 EP disclosed
US-20040127488-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127488-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 ABCB1 628/4885KCNE1 3515/4885KCNQ1 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.